Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Cancer stem cells (CSCs) exhibit enhanced chemo/radiotherapy resistance, and their survival following cancer treatment is believed to be responsible for tumor recurrence and metastasis. Thus, understanding the mechanisms through which CSCs survive conventional chemotherapy is essential for identification of new therapeutic strategies to prevent tumor relapse. Our findings that ovarian CSCs survive cisplatin treatment through elevated expression of polymerase η represent an opportunity to eradicate CSCs and improve the survival of ovarian cancer patients. In addition, identification of miR-93 as the regulator of polymerase η expression provides a target to increase the efficacy of cisplatin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, this DNA polymerase was shown to be induced in several human cell lines after treatment with chemotherapeutic agents in a p53-dependent manner, and was linked to acquired resistance to chemotherapy ( 24 , 25 ).”
From Predominant role of DNA polymerase eta and p53-dependent translesion synthesis in the survival of ultraviolet-irradiated human cells (2017) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The upregulation of miR-93, a microRNA that triggers pol η degradation, also enhanced the effect of cisplatin [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
Experimental — accuracy not yet measuredIn the citing paper
“The protective role of TLS in cancer is revealed by the overexpression of pol η in ovarian-cancer cells, which is evidenced in populations that resist cisplatin treatment [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
In the citing paper
“The protective role of TLS in cancer is revealed by the overexpression of pol η in ovarian-cancer cells”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
In the citing paper
“The effect of cisplatin was enhanced when simultaneously depleting pol η in ovarian-cancer-cell models [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051 · cited 1×
“The CD44CD117 cells, SP cells, ALDH cells, and spheroid cells isolated from both ovarian cancer cell lines and primary human ovarian tumors fulfill all currently accepted criteria for the existence of a subpopulation of tumor-initiating cells (19, 22, 23).”
BackgroundDirect Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391 · cited 1×
“These cross-links block DNA replication and invoke apoptosis in rapidly dividing cells (5).”
BackgroundIdentification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293 · cited 15×
“Ovarian CSCs have been successfully isolated, based on the expression of distinctive cell surface markers CD44 and CD117 (18, 19), their ability to efflux the Hoechst 33342 fluorescent dye (Side population, SP) (20), the activity of ALDH (21), and their ability to grow as floating spheres in serum-free medium (19).”
BackgroundMethodInfluentialCancer Stem Cells: Models and Concepts
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.062105.204854 · Cited by 1,274 · cited 1×
“The CD44CD117 cells, SP cells, ALDH cells, and spheroid cells isolated from both ovarian cancer cell lines and primary human ovarian tumors fulfill all currently accepted criteria for the existence of a subpopulation of tumor-initiating cells (19, 22, 23).”
BackgroundCancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171 · cited 1×
“Thus, this reduced expression of MCM7, probably due to relative quiescence of CSCs (49, 50), could be a contributor to the decreased expression of miR-93 in CSCs.”
BackgroundOvarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154 · cited 2×
“Cancer Chemother Pharmacol 39(3):245–253.”
BackgroundSide Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells
Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3557 · Cited by 947 · cited 1×
“Although MCM7 overexpression has been identified in various tumors and considered a bad prognostic indicator in prostate cancer (45, 46), MCM7 expression is lower in various CSCs, including SP of human lung cancer cells (47) and prostate cancer cells (48), as well as ALDH+ breast cancer cells (41).”
BackgroundMechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869 · cited 6×
“Among many polymerases tested in vitro, the Y-family DNA Pol η is the most efficient and accurate at bypassing Pt-GG lesions (10, 37, 38).”
MethodInfluentialBertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., Pratesi, G., Fabbri, A., Andriani, F., Tinelli, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905653106 · Cited by 767 · cited 1×
“Cisplatin treatment is capable of inducing enrichment in a population of cells with CSC properties, probably due to killing of cisplatin-sensitive bulk cancer cells and survival of cisplatinresistant CSCs (33, 34).”
BackgroundCisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615 · cited 1×
“cis-diamminedichloroplatinum(II) (cisplatin), the first member of Pt-based chemotherapeutic agents, has been widely used to treat various malignant tumors, including ovarian cancer (4).”
BackgroundSilva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Ginestier, C., Johnston, C., Kueck, A., Reynolds, R. K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3175 · Cited by 514 · cited 4×
“However, highly depleted miR-93 was found in mouse mammary stem cells characterized with ALDH+ (40) and breast CSCs characterized by their expression of ALDH+ or CD44+CD24− (41).”
BackgroundInfluentialMechanisms of accurate translesion synthesis by human DNA polymerase η
Masutani, C., Kusumoto, R., Iwai, S., & Hanaoka, F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.3100 · Cited by 504 · cited 1×
“Among many polymerases tested in vitro, the Y-family DNA Pol η is the most efficient and accurate at bypassing Pt-GG lesions (10, 37, 38).”
BackgroundAlvero, A. B., Chen, R., Fu, H.-H., Montagna, M., Schwartz, P. E., Rutherford, T., Silasi, D.-A., Steffensen, K. D., Waldstrom, M., Visintin, I., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7533 · Cited by 489
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397 · cited 1×
“The cisplatin-induced DNA cross-links are primarily removed by the nucleotide excision repair (NER) pathway (6) or bypassed during replication through translesion DNA synthesis (TLS) (7–10).”
BackgroundRecognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F., & Papaccio, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 395 · cited 1×
“No significant reduction of Pt-GG formation was found in another CSC population isolated from ovarian cancer cell line SKOV3 based on the spheroid formation (27, 28) (SI Appendix, Fig.”
BackgroundPetrocca, F., Vecchione, A., & Croce, C. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1768 · Cited by 385 · cited 2×
“miR-93 is located at chromosome 7q22, in the intron 13 of the host gene minichromosome maintenance 7 (MCM7), where they are cotranscribed in the context of MCM7 primary transcript (39).”
BackgroundMann, S. C., Andrews, P. A., & Howell, S. B. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684878 · Cited by 349
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206400109 · Cited by 328 · cited 1×
“Ovarian CSCs have been successfully isolated, based on the expression of distinctive cell surface markers CD44 and CD117 (18, 19), their ability to efflux the Hoechst 33342 fluorescent dye (Side population, SP) (20), the activity of ALDH (21), and their ability to grow as floating spheres in serum-free medium (19).”
BackgroundMicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8
Fang, L., Deng, Z., Shatseva, T., Yang, J., Peng, C., Du, W. W., Yee, A. J., Ang, L. C., He, C., Shan, S. W., et al. (2011) · Oncogene · doi:10.1038/onc.2010.465 · Cited by 307 · cited 1×
“miR-93 is able to enhance cell survival, promote sphere formation, and augment tumor growth by targeting integrin-β8 in the glioblastoma U87 cell line (42).”
BackgroundTwo-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284 · cited 3×
“One of the important cell survival mechanisms following cisplatin treatment is TLS, which is mediated by specialized DNA Pols (11).”
BackgroundMethodReardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
Morrison, R., Schleicher, S. M., Sun, Y., Niermann, K. J., Kim, S., Spratt, D. E., Chung, C. H., & Lu, B. (2011) · Journal of Oncology · doi:10.1155/2011/941876 · Cited by 247 · cited 1×
“Inefficient formation of DNA lesions and enhanced DNA repair have been implicated in cancer therapy resistance in CSCs (24).”
BackgroundMicroRNA Regulation of Cancer Stem Cells
Liu, C., & Tang, D. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1035 · Cited by 242 · cited 1×
“Micro RNAs (miRNAs) can be differentially expressed in CSCs and regulate their characteristics (35).”
BackgroundError-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 219 · cited 1×
“S15 C and D), although it has been reported that REV1 or REV3L depletion sensitized lymphoma to cisplatin (14), and REV3L depletion sensitized lung adenocarcinoma to cisplatin (17).”
BackgroundA role for microRNAs in maintenance of mouse mammary epithelial progenitor cells
Ibarra, I., Erlich, Y., Muthuswamy, S. K., Sachidanandam, R., & Hannon, G. J. (2007) · Genes & Development · doi:10.1101/gad.1616307 · Cited by 218
Abubaker, K., Latifi, A., Luwor, R., Nazaretian, S., Zhu, H., Quinn, M. A., Thompson, E. W., Findlay, J. K., & Ahmed, N. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-24 · Cited by 213
Vaisman, A., Masutani, C., Hanaoka, F., & Chaney, S. G. (2000) · Biochemistry · doi:10.1021/bi000130k · Cited by 211 · cited 1×
“Among many polymerases tested in vitro, the Y-family DNA Pol η is the most efficient and accurate at bypassing Pt-GG lesions (10, 37, 38).”
BackgroundDoles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190 · cited 1×
“S15 C and D), although it has been reported that REV1 or REV3L depletion sensitized lymphoma to cisplatin (14), and REV3L depletion sensitized lung adenocarcinoma to cisplatin (17).”
BackgroundMamenta, E. L., Poma, E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., & Chaney, S. G. (1994) · PubMed · Cited by 181
MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells
Liu, S., Patel, S. H., Ginestier, C., Ibarra, I., Martin-Trevino, R., Bai, S., McDermott, S. P., Shang, L., Ke, J., Ou, S. J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002751 · Cited by 166 · cited 4×
“In contrast, miR-93 was reported to inhibit tumor growth and metastasis by decreasing the CSC population in SUM159 breast cancer cells (41).”
BackgroundInfluentialStructural basis of human DNA polymerase η-mediated chemoresistance to cisplatin
Zhao, Y., Biertümpfel, C., Gregory, M. T., Hua, Y.-J., Hanaoka, F., & Yang, W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202681109 · Cited by 160
The Role of DNA Polymerase η in Translesion Synthesis Past Platinum–DNA Adducts in Human Fibroblasts
Bassett, E., King, N. M., Bryant, M. F., Hector, S., Pendyala, L., Chaney, S. G., & Cordeiro‐Stone, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1328 · Cited by 139 · cited 1×
“Among many polymerases tested in vitro, the Y-family DNA Pol η is the most efficient and accurate at bypassing Pt-GG lesions (10, 37, 38).”
BackgroundA Novel Role of DNA Polymerase η in Modulating Cellular Sensitivity to Chemotherapeutic Agents
Chen, Y.-W., Cleaver, J. E., Hanaoka, F., Chang, C.-F., & Chou, K.-M. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0118 · Cited by 122 · cited 1×
“Pol η down-regulation results in increased sensitivity to cisplatin (13), whereas the increased Pol η level reduces the effectiveness of chemotherapy and the survival time of patients with non–small-cell lung cancer or metastatic gastric adenocarcinoma (30).”
BackgroundManagement of Platinum-Sensitive Recurrent Ovarian Cancer
Pfisterer, J., & Ledermann, J. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.012 · Cited by 121 · cited 2×
“The mainline treatment of ovarian cancer is cytoreductive surgery followed by platinum (Pt)-based chemotherapy (2).”
BackgroundChemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway
Singh, S., Chitkara, D., Mehrazin, R., Behrman, S. W., Wake, R. W., & Mahato, R. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040021 · Cited by 115 · cited 2×
“Proc Natl Acad Sci USA 107(48):20792–20797.”
BackgroundAKT involvement in cisplatin chemoresistance of human uterine cancer cells
Gagnon, V., Mathieu, I., Sexton, É., Leblanc, K., & Asselin, É. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.06.023 · Cited by 112 · cited 1×
“Given that elevated expression of STAT3 and AKT3 is associated with cisplatin resistance in various cancers (43, 44), it is possible that the low level of miR-93 also contributes to cisplatin resistance through affecting other critical pathways.”
BackgroundCeppi, P., Novello, S., Cambieri, A., Longo, M., Monica, V., Lo Iacono, M., Giaj-Levra, M., Saviozzi, S., Volante, M., Papotti, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1227 · Cited by 96
EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients
Laitinen, S., MARTIKAINEN, P. M., Tolonen, T. T., Isola, J. J., Tammela, T. L. J., & Visakorpi, T. (2007) · International Journal of Cancer · doi:10.1002/ijc.23145 · Cited by 90 · cited 1×
“Although MCM7 overexpression has been identified in various tumors and considered a bad prognostic indicator in prostate cancer (45, 46), MCM7 expression is lower in various CSCs, including SP of human lung cancer cells (47) and prostate cancer cells (48), as well as ALDH+ breast cancer cells (41).”
BackgroundLi, J., Delmastro, D. A., Vaisman, A., Solle, M., & Chaney, S. G. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050568 · Cited by 74
Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer
Ji, T., Gong, D., Han, Z., Xiao, W., Yan, Y., Ye, F., Ding, W., Wang, J., Xia, X., Li, F., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.022 · Cited by 74 · cited 1×
“Given that elevated expression of STAT3 and AKT3 is associated with cisplatin resistance in various cancers (43, 44), it is possible that the low level of miR-93 also contributes to cisplatin resistance through affecting other critical pathways.”
BackgroundZhou, W., Chen, Y., Liu, X., Chu, P. G., Loria, S., Wang, Y., Yen, Y., & Chou, K.-M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083978 · Cited by 67
Teng, K.-Y., Qiu, M., Li, Z. H., Luo, H., Zeng, Z.-L., Luo, R.-Z., Zhang, H.-Z., Wang, Z., Li, Y., & Xu, R. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-126 · Cited by 66
DNA Polymerase ζ Is a Major Determinant of Resistance to Platinum-Based Chemotherapeutic Agents
Sharma, S., Shah, N. A., Joiner, A. M., Roberts, K. H., & Canman, C. E. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076828 · Cited by 66
Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells
Lin, X., Okuda, T., Trang, J., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020446 · Cited by 62
DDB2 Suppresses Tumorigenicity by Limiting the Cancer Stem Cell Population in Ovarian Cancer
Han, C., Zhao, R., Liu, X., Srivastava, A. K., Gong, L., Mao, H. C., Qu, M., Zhao, W., Yu, J., & Wang, Q. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0638 · Cited by 54 · cited 2×
“CD44CD117 cells were isolated from ovarian cancer cell lines 2008 and C13 (25, 26) by using fluorescence-activated cell sorting (FACS) and have been considered CSCs based on their characteristics (19, 27).”
BackgroundMethodSelf-citationThe MCM helicase: linking checkpoints to the replication fork
Forsburg, S. L. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360114 · Cited by 53 · cited 1×
“Thus, this reduced expression of MCM7, probably due to relative quiescence of CSCs (49, 50), could be a contributor to the decreased expression of miR-93 in CSCs.”
BackgroundFischhaber, P. L., & Friedberg, E. C. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.08.011 · Cited by 25
Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases
Levesque, M.-H., Elalfy, M., Berger, L., Labrie, F., & Labrie, C. (2007) · Urology · doi:10.1016/j.urology.2006.11.001 · Cited by 23 · cited 1×
“Although MCM7 overexpression has been identified in various tumors and considered a bad prognostic indicator in prostate cancer (45, 46), MCM7 expression is lower in various CSCs, including SP of human lung cancer cells (47) and prostate cancer cells (48), as well as ALDH+ breast cancer cells (41).”
Background
Cited by
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
“Srivastava found that enhanced expression of DNA polymerase contributes to cisplatin resistance in ovarian CSCs.(135) In contrast, pharmacological inhibition of the DNA damage checkpoints CHK1 and CHK2 sensitized CSCs to radiotherapy.”
BackgroundSelf-citationDNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
“A recent report showed elevated PolZ expression in ovarian cancer stem cells isolated from ovarian cancer cell lines and primary tumors (77).”
BackgroundAdvances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Vitale, I., Manic, G., De Maria, R., Kroemer, G., & Galluzzi, L. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.006 · Cited by 361
“Accordingly, genetic inhibition of POLH by small interfering RNAs (siRNAs) or microRNAs (miRNAs) reportedly sensitizes ovarian CSCs to the genotoxic effects of cisplatin, in vitro and in vivo (Srivastava et al., 2015) (Figure 2).”
BackgroundNon-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Metadata
- Authors
- Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E.
- Affiliations
- Department of Radiology,
- Department of Molecular Virology, Immunology and Medical Genetics,
- Comprehensive Cancer Center,
- Department of Pathology,
- Center for Biostatistics, and
- The Ohio State University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-03-23
- Volume
- 112
- Issue
- 14
- Pages
- 4411-4416
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4394248
- OpenAlex
- W2035233698
- Cited by
- 188
- References
- 51
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 18 · 2022: 16 · 2021: 14 · 2020: 22 · 2019: 18 · 2018: 23 · 2017: 20 · 2016: 20 · 2015: 7
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Health (CA151248)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- DNA polymerase eta, cisplatin resistance, ovarian cancer stem cells, translesion synthesis, chemoresistance, miR-93, apoptosis, tumor recurrence, DNA damage response
- MeSH terms
- Y-Family DNA Polymerases, Animals, Cell Survival, Cisplatin, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, Female, Flow Cytometry, Humans, Mice, Nude, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Transplantation, Ovarian Neoplasms, Recurrence, Neoplastic Stem Cells, Down-Regulation, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.